Standout Papers

Drug repurposing: progress, ch... 2001 2026 2009 2017 2.8k
  1. Drug repurposing: progress, challenges and recommendations (2018)
    Sudeep Pushpakom, Francesco Iorio et al. Nature Reviews Drug Discovery
  2. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients (2004)
    Munir Pirmohamed, Chris Green et al. BMJ
  3. Phase I Clinical Trial of Oral Curcumin (2004)
    Ricky A. Sharma, Darren N. Cooke et al. Clinical Cancer Research
  4. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin (2009)
    Ann K. Daly, Peter T. Donaldson et al. Nature Genetics
  5. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. (2001)
    Ricky A. Sharma, Christopher R. Ireson et al. PubMed
  6. A Randomized Trial of Genotype-Guided Dosing of Warfarin (2013)
    Munir Pirmohamed, Girvan Burnside et al. New England Journal of Medicine
  7. Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes (2009)
    Emma Davies, Christopher F. Green et al. PLoS ONE
  8. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing (2011)
    J. A. Johnson, Li Gong et al. Clinical Pharmacology & Therapeutics
  9. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update (2017)
    JA Johnson, Li Gong et al. Clinical Pharmacology & Therapeutics
  10. Pharmacogenomics: current status and future perspectives (2023)
    Munir Pirmohamed Nature Reviews Genetics

Immediate Impact

6 by Nobel laureates 9 from Science/Nature 73 standout
Sub-graph 1 of 23

Citing Papers

A foundation model for clinician-centered drug repurposing
2024 Standout
Rational Design in Photopharmacology with Molecular Photoswitches
2023 StandoutNobel
2 intermediate papers

Works of Munir Pirmohamed being referenced

Drug repurposing: progress, challenges and recommendations
2018 Standout
Current Assessment of Risk–Benefit by Regulators: Is It Time to Introduce Decision Analyses?
2007
and 1 more

Author Peers

Author Last Decade Papers Cites
Munir Pirmohamed 8227 7392 5109 5843 590 32.8k
Pertti J. Neuvonen 10773 3993 5711 3070 506 26.1k
Teri E. Klein 12310 3485 6089 6937 349 28.9k
Jerry Avorn 3132 2246 3484 1254 511 37.6k
Thomas Efferth 4548 3263 597 16836 944 35.4k
Jos H. Beijnen 5934 3184 7426 17376 1.5k 56.8k
Bruno H. Stricker 1548 2101 1568 3579 558 29.4k
Magnus Ingelman‐Sundberg 17831 3020 2932 10603 523 34.7k
Howard L. McLeod 6442 1780 2578 9356 476 26.0k
Leslie Z. Benet 8306 3793 6099 4902 502 26.1k
Toine C. G. Egberts 1204 1978 3166 1037 510 17.4k

All Works

Loading papers...

Rankless by CCL
2026